Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance

BMC Pregnancy and Childbirth

Volumn 14, Issue 1, 2014, Pages

  Hanley, Gillian E ^a,b   Mintzes, Barbara ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Administrative data; Anxiety; Depression; Pregnancy; Prescription drugs; Psychiatric conditions in pregnancy; Psychotropic medicines

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; DESVENLAFAXINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PROCHLORPERAZINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; SCOPOLAMINE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZALEPLON; ZOLPIDEM; BENZODIAZEPINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; ANTIEMETIC AGENT; BENZODIAZEPINE;

ACUTE STRESS DISORDER; ADJUSTMENT DISORDER; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COHORT ANALYSIS; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; OUTPATIENT DEPARTMENT; PERSONALITY DISORDER; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIMIGRAVIDA; PRIVATE HEALTH INSURANCE; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SECOND TRIMESTER PREGNANCY; SLEEP DISORDER; THIRD TRIMESTER PREGNANCY; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEPRESSION; HEALTH INSURANCE; MENTAL DISORDERS; PREGNANCY COMPLICATIONS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMPLOYEE; HOSPITALIZATION; MEDICAL INFORMATION; MENTAL PATIENT; OUTPATIENT CARE; PREDICTIVE VALUE; PREGNANT WOMAN; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREND STUDY;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZODIAZEPINES; DEPRESSION; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSURANCE, HEALTH; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; YOUNG ADULT;

EID: 84904535097     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-14-242     Document Type: Article

References (49)

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007, 196(6):544e1-544e5.
2. Muzik M, Marcus SM, Heringhausen JE, Flynn H. When depression complicates childbearing: guidelines for screening and treatment during antenatal and postpartum obstetric care. Obstet Gynecol Clin North Am 2009, 36(4):771-788.
3. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005, 106(5):1071-1083.
4. Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, Swinson T, Gartlehner G, Brody S, Miller WC. Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes: Summary 2005,
5. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008, 65(7):805-815.
6. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012, 135(1):71-77.
7. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012, 344:d8012.
8. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011, 72(7):979-985.
9. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63(8):898-906.
10. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006). Clin Ther 2011, 34(1):239-249.
11. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Safety 2011, 20(2):177-184.
12. McKenna K, Einarson A, Levinson A, Koren G. Significant changes in antipsychotic drug use during pregnancy. Vet Hum Toxicol 2004, 46(1):44-46.
13. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723.
14. Figueiredo B, Conde A. Anxiety and depression in women and men from early pregnancy to 3-months postpartum. Arch Women's Mental Health 2011, 14(3):247-255.
15. Grigoriadis S, De CM, Barrons E, Bradley L, Eady A, Fishell A, Mamisachvili L, Cook GS, O'Keefe M, Romans S, Ross LE. Mood and anxiety disorders in a sample of Canadian perinatal women referred for psychiatric care. Arch Women's Mental Health 2011, 14(4):325-333.
16. Swanson LM, Pickett SM, Flynn H, Armitage R. Relationships among depression, anxiety, and insomnia symptoms in perinatal women seeking mental health treatment. J Women's Health 2011, 20(4):553-558.
17. Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, Hammad TA, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffenreffer K, Johnson KE, Toh S. Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf 2013, 22(5):524-532.
18. Huybrechts KF, Palmsten K, Mogun H, Kowal M, Avorn J, Setoguchi-Iwata S, Hernandez-Diaz S. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry 2013, 35(3):265-271.
19. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010, 67(10):1012-1024.
20. Alder J, Fink N, Bitzer J, Hösli I, Holzgreve W. Depression and anxiety during pregnancy: A risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern-Fetal Neo M 2007, 20(3):189-209.
21. Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000, 19(6):535-543.
22. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992, 45(10):1093-1099.
23. Kozhimannil KB, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. JAMA 2009, 301(8):842-847.
24. Haelterman E, Breart G, Paris-Liado J, Dramaix M, Tchobroutsky C. Effect of uncomplicated chronic hypertension on the risk of small-for-gestational age birth. Am J Epidemiol 1997, 145(8):689-695.
25. Dayan J, Creveuil C, Herlicoviez M, Herbel C, Baranger E, Savoye C, Thouin A. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002, 155(4):293-301.
26. Mintzes B, Wright JM. Are antidepressants safe in pregnancy? A focus on SSRIs. Therapeut Lett 2010, 76:1-2.
27. Mintzes B, Fortin PM, Wright JM. Antidépresseurs et grossesse: Les inhibiteurs spécifiques de la recapture de la sérotonine. Médecine 2010, 6(6):255-257.
28. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002, 53(1):39-49.
29. Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations. Drug Saf 2005, 28(8):695-706.
30. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013, 70(4):436-443.
31. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010, 182(10):1031-1037.
32. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS ONE 2014, 9(3):e92778.
33. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339:b3569-b3575.
34. Jong GW, Einarson T, Koren G, Einarson A. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): A systematic review. Reprod Toxicol 2012, 34(3):293-297.
35. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015.
36. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002, 156(11):1129-1132.
37. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60(7):720-726.
38. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004, 158(4):312-316.
39. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004, 65(2):230-237.
40. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011, 24(1):34-40.
41. McCauley-Elsom K, Gurvich C, Elsom SJ, Kulkarni J. Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs 2010, 17(2):97-104.
42. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013, 35(1):3-8.
43. Hudak ML, Tan RC, . Committee On DRUGS, Committee on Fetus and NEWBORN, American Academy of P Neonatal Drug Withdrawal. Pediatrics 2012, 129(2):e540-e560. Committee On DRUGS, Committee on Fetus and NEWBORN, American Academy of P.
44. Wang LH, Lin HC, Lin CC, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther 2010, 88(3):369-374.
45. Reeves WC, Strine TW, Pratt LA, Thompson W, Ahluwalia I, Dhingra SS, McKnight-Eily LR, Harrison L, D'Angelo DV, Williams L, Morrow B, Gould D, Safran MA, . Centers for Disease Control and Prevention (CDC) Mental illness surveillance among adults in the United States. Morb Mortal Wkly Rep Surveill Summ 2011, 60(Suppl 3):1-29. Centers for Disease Control and Prevention (CDC).
46. FDA Compazine prescribing information: brand of prochlorperazine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/010571s096lbl.pdf, FDA.
47. Markus AR, Rosenbaum S. The role of Medicaid in promoting access to high-quality, high-value maternity care. Womens Health Issues 2010, 20(1 Suppl):S67-S78.
48. Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, Huybrechts KF. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology 2014, In press.
49. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood) 2011, 30(8):1434-1442.